Allergan plc (NYSE:AGN) Stock Position Lowered by Stephens Inc. AR

Stephens Inc. AR lessened its position in Allergan plc (NYSE:AGN) by 7.5% in the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 22,560 shares of the company’s stock after selling 1,822 shares during the quarter. Stephens Inc. AR’s holdings in Allergan were worth $3,777,000 as of its most recent filing with the SEC.

Several other large investors have also recently modified their holdings of the stock. Dimensional Fund Advisors LP lifted its position in Allergan by 0.8% during the fourth quarter. Dimensional Fund Advisors LP now owns 1,606,982 shares of the company’s stock worth $214,787,000 after buying an additional 13,100 shares in the last quarter. Geode Capital Management LLC lifted its position in Allergan by 6.6% during the fourth quarter. Geode Capital Management LLC now owns 4,000,839 shares of the company’s stock worth $533,767,000 after buying an additional 247,743 shares in the last quarter. Carroll Financial Associates Inc. lifted its position in Allergan by 6.7% during the first quarter. Carroll Financial Associates Inc. now owns 1,675 shares of the company’s stock worth $245,000 after buying an additional 105 shares in the last quarter. Wedbush Securities Inc. lifted its position in Allergan by 18.9% during the first quarter. Wedbush Securities Inc. now owns 8,089 shares of the company’s stock worth $1,184,000 after buying an additional 1,284 shares in the last quarter. Finally, Liberty Wealth Management LLC lifted its position in Allergan by 108.8% during the first quarter. Liberty Wealth Management LLC now owns 190 shares of the company’s stock worth $27,000 after buying an additional 99 shares in the last quarter. Institutional investors and hedge funds own 77.81% of the company’s stock.

NYSE:AGN traded up $1.91 on Friday, reaching $158.25. The company’s stock had a trading volume of 3,003,600 shares, compared to its average volume of 4,834,278. Allergan plc has a 12-month low of $114.27 and a 12-month high of $197.00. The company has a quick ratio of 1.49, a current ratio of 1.03 and a debt-to-equity ratio of 0.34. The firm has a market cap of $51.91 billion, a price-to-earnings ratio of 9.48, a price-to-earnings-growth ratio of 1.63 and a beta of 1.63. The stock has a 50 day moving average price of $163.21 and a 200 day moving average price of $145.59.

Allergan (NYSE:AGN) last posted its earnings results on Tuesday, August 6th. The company reported $4.38 EPS for the quarter, beating the Zacks’ consensus estimate of $4.34 by $0.04. Allergan had a positive return on equity of 8.73% and a negative net margin of 54.25%. The company had revenue of $4.09 billion for the quarter, compared to the consensus estimate of $3.93 billion. During the same quarter in the previous year, the business earned $4.42 earnings per share. The company’s revenue for the quarter was down .8% on a year-over-year basis. Equities research analysts expect that Allergan plc will post 16.68 EPS for the current fiscal year.

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Investors of record on Tuesday, August 13th will be issued a $0.74 dividend. The ex-dividend date of this dividend is Monday, August 12th. This represents a $2.96 annualized dividend and a dividend yield of 1.87%. Allergan’s dividend payout ratio is presently 17.74%.

A number of equities analysts recently commented on the company. Barclays lifted their price objective on Allergan from $176.00 to $188.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 7th. Goldman Sachs Group assumed coverage on Allergan in a research report on Tuesday, May 28th. They set a “neutral” rating and a $154.00 price objective on the stock. Wells Fargo & Co reiterated a “buy” rating and set a $176.00 price objective (down previously from $188.00) on shares of Allergan in a research report on Wednesday. TheStreet upgraded Allergan from a “d+” rating to a “c” rating in a research report on Friday, July 12th. Finally, SunTrust Banks lifted their price objective on Allergan to $185.00 and gave the stock a “buy” rating in a research report on Wednesday, July 3rd. Two equities research analysts have rated the stock with a sell rating, fifteen have issued a hold rating and seven have assigned a buy rating to the company. The stock currently has an average rating of “Hold” and an average target price of $179.43.

About Allergan

Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.

Further Reading: How is a buy-side analyst different from a sell-side analyst?

Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).

Institutional Ownership by Quarter for Allergan (NYSE:AGN)

Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.